Business Description
Prestige Consumer Healthcare Inc
NAICS : 325412
SIC : 2834
ISIN : US74112D1019
Description
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.05 | |||||
| Equity-to-Asset | 0.48 | |||||
| Debt-to-Equity | 0.76 | |||||
| Debt-to-EBITDA | 112.86 | |||||
| Interest Coverage | 4.93 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 2.16 | |||||
| Beneish M-Score | -2.29 | |||||
| WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 6.3 | |||||
| 3-Year EBITDA Growth Rate | -70.6 | |||||
| 3-Year EPS without NRI Growth Rate | 19.9 | |||||
| 3-Year FCF Growth Rate | 3.9 | |||||
| 3-Year Book Growth Rate | 7.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 8 | |||||
| Future 3-5Y Total Revenue Growth Rate | 1.82 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 37.72 | |||||
| 9-Day RSI | 45.82 | |||||
| 14-Day RSI | 47.95 | |||||
| 6-1 Month Momentum % | 16.57 | |||||
| 12-1 Month Momentum % | 13.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.09 | |||||
| Quick Ratio | 1.92 | |||||
| Cash Ratio | 0.5 | |||||
| Days Inventory | 115.06 | |||||
| Days Sales Outstanding | 53.49 | |||||
| Days Payable | 38.61 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 0.3 | |||||
| Shareholder Yield % | 5.92 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 55.23 | |||||
| Operating Margin % | 30.81 | |||||
| Net Margin % | -7.11 | |||||
| FCF Margin % | 20.46 | |||||
| ROE % | -5.2 | |||||
| ROA % | -2.36 | |||||
| ROIC % | 9.6 | |||||
| ROC (Joel Greenblatt) % | -7 | |||||
| ROCE % | -0.61 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 15.24 | |||||
| PE Ratio without NRI | 16.43 | |||||
| Shiller PE Ratio | 26.33 | |||||
| PS Ratio | 3.09 | |||||
| PB Ratio | 2.17 | |||||
| Price-to-Free-Cash-Flow | 15.1 | |||||
| Price-to-Operating-Cash-Flow | 14.53 | |||||
| EV-to-EBIT | -231.93 | |||||
| EV-to-Forward-EBIT | 12.94 | |||||
| EV-to-EBITDA | 430.18 | |||||
| EV-to-Forward-EBITDA | 11.99 | |||||
| EV-to-Revenue | 4.08 | |||||
| EV-to-Forward-Revenue | 3.98 | |||||
| EV-to-FCF | 19.93 | |||||
| Price-to-Projected-FCF | 1.06 | |||||
| Price-to-Median-PS-Value | 1.14 | |||||
| Earnings Yield (Greenblatt) % | -0.43 | |||||
| FCF Yield % | 6.68 | |||||
| Forward Rate of Return (Yacktman) % | -30.32 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers